The recent FDA decision will likely mean more Medicare patients gain access to the blockbuster weight loss drug, experts say. Meanwhile, results continue to roll in for GLP-1 agonists for conditions beyond diab
Who's a good candidate for taking the drug to reduce cardiac risk? The FDA's approval expands the use of semaglutide to people with a BMI of 27 or higher (qualified as overweight or obese) with a history of cardiac events. But it's unknown whether the drug would work...
The recent FDA decision will likely mean more Medicare patients gain access to the blockbuster weight loss drug, experts say. Meanwhile, results continue to roll in for GLP-1 agonists for conditions beyond diabetes and obesity.
In March, 2024, the FDA approved Wegovy for adults with cardiovascular disease and obesity or overweight based on an extensive scientific study of the drug. The study showed that Wegovy significantly lowers the odds of a heart attack, stroke, and cardiac death. The drug also helps with weight...
Wegovy, produced by Danish pharmaceutical giant Novo Nordisk, was approved "to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight," the FDA said in a statement. ...
EU panel follows FDA’s lead on Wegovy, recommending use to prevent cardiac events European regulators are poised to approve Novo Nordisk’s blockbuster drug Wegovy to reduce the risk of cardiovascu...
Latest FDA alerts (4) Side effects Dosage information During pregnancy Support group FDA approval history Drug class: GLP-1 Agonists (Incretin Mimetics) Breastfeeding Patient resources Wegovy drug information Professional resources Semaglutide monograph Other brands Ozempic, Rybelsus Related treatment guide...
The FDAapproved semaglutide (Wegovy)opens in a new tab or windowto reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight, the agency announced on Friday.
cells of the pancreas, and only when blood sugar is elevated. Kolata takes us step-by-step through the development, after many years, of a GLP-1 diabetes drug that can be injected only once a week. In 2017 the Danish company Novo Nordisk got FDA approval to market it as “Ozempic.”...
Novo Nordiskstudied Wegovy against placebo in addition to standard of care for prevention of major adverse cardiac events in 17,604 adults with heart disease and obesity or who were overweight, but who didn’t have diabetes. It called the five-year trial “Select.” ...